| DrugRepV_0073 | Sunitinib-Erlotinib | NA | NA | Ebola virus | rVSV-GP EBOV | NA | Flow cytometry | Decrease | NA | 28240606 |
| DrugRepV_0477 | Aripiprazole | Nervous System | Schizophrenia | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0478 | Astemizole | Respiratory System | Allergies | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0479 | Atovaquone | Antiparasitic products, Insectisides and Repellents | Malaria | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Approved | 26041706 |
| DrugRepV_0480 | Azacitidine | Antineoplastic and Immunomodulating Agents | French-American-British myelodysplastic syndrome | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Approved | 26041706 |
| DrugRepV_0481 | Benztropine | Nervous System | Parkinson disease | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0482 | Bepridil | Cardiovascular agents | Hypertension and angina | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0483 | Clemastine | Respiratory System | Allergic rhinitis | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0484 | Clomiphene | Genito Urinary System and Sex Hormones | Polycystic ovary syndrome | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0485 | Clomipramine | Nervous System | Depression, schizophrenia, Tourette disorder | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0486 | Dasatinib | Antineoplastic and Immunomodulating Agents | Cancer | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0487 | Efavirenz | Antiinfectives For Systemic Use | Acquired immunodeficiency syndrome | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0488 | Flupentixol | Nervous System | Schizophrenia | Depression | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Investigational, Withdrawn | 26041706 |
| DrugRepV_0489 | Fluphenazine | Nervous System | Psychosis | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0490 | Hycanthone | Antischistosomal | Parasitic infections | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Experimental | 26041706 |
| DrugRepV_0491 | Lomerizine | Neurologic-agent | Migraine disorders | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Experimental | 26041706 |
| DrugRepV_0492 | Maprotiline | Nervous System | Bipolar depression | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Investigational | 26041706 |
| DrugRepV_0493 | Mycophenolate Mofetil | Immunosuppressant | Organ rejection (immunosuppressants) | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Approved, Investigational | 26041706 |
| DrugRepV_0494 | Paroxetine | Nervous System | Major depressive disorder (MDD) | Panic disorder | Obsessive-compulsive disorder (OCD) | Social anxiety disorder (social phobia) | Generalized anxiety disorder (GAD) | Post-traumatic stress disorder (PTSD) | Premenstrual dysphoric disorder (PMDD) | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Investigational | 26041706 |
| DrugRepV_0495 | Pimozide | Nervous System | Tourette Disorder | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0496 | Piperacetazine | Antipsychotic | Schizophrenia | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | NA | 26041706 |
| DrugRepV_0497 | Prochlorperazine | Nervous System | Nausea | Vomiting | Schizophrenia | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0498 | Quinacrine | NA | Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Investigational | 26041706 |
| DrugRepV_0499 | Sertraline | Nervous System | Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0500 | Simvastatin | Cardiovascular agents | Hypercholesterolemia | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0501 | Strophanthin | Cardiovascular agents | Atrial fibrillation | Flutter | Heart failure | Ebola virus | EBOV-VLP | NA | Flow cytometry | No significant effect | Approved | 26041706 |
| DrugRepV_0502 | Teicoplanin | Antiinfectives For Systemic Use | Bacterial infections | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0503 | Terconazole | Genito Urinary System and Sex Hormones | Candidiasis (a yeast-like fungal infection) of the vulva and vagina | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0504 | Thioridazine | Nervous System | Schizophrenia | Anxiety disorder | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Withdrawn | 26041706 |
| DrugRepV_0505 | Toremifene | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved, Investigational | 26041706 |
| DrugRepV_0506 | Vinorelbine | Antineoplastic and Immunomodulating Agents | Breast cancer and non-small cell lung cancer (NSCLC) | Ebola virus | EBOV-VLP | NA | Flow cytometry | Decrease (>90 %) | Approved | 26041706 |
| DrugRepV_0603 | Clomiphene Citrate | Genito Urinary System and Sex Hormones | Female infertility | Ebola virus | VLP-GP | NA | Flow cytometry | Decrease (93 %) | Approved | 23785035 |
| DrugRepV_0604 | Toremifene Citrate | Antineoplastic and Immunomodulating Agents | Breast Cancer | Ebola virus | VLP-GP | NA | Flow cytometry | Decrease (95 %) | Approved, Investigational | 23785035 |
| DrugRepV_1534 | Daptomycin | Antiinfectives For Systemic Use | Bacterial infections | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1535 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational, Vet approved | 27476412 |
| DrugRepV_1536 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27476412 |
| DrugRepV_1537 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1538 | Sertraline | Nervous System | Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder | Zika virus | MEX_I_7 | NA | Flow cytometry | No significant effect (50 %) | Approved | 27476412 |
| DrugRepV_1539 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | Zika virus | MEX_I_7 | NA | Flow cytometry | No significant effect (50 %) | Approved | 27476412 |
| DrugRepV_1540 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1541 | Daptomycin | Antiinfectives For Systemic Use | Bacterial infections | Zika virus | MEX_I_7 | NA | Flow cytometry | No significant effect (50 %) | Approved | 27476412 |
| DrugRepV_1542 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | Zika virus | MEX_I_7 | NA | Flow cytometry | Increase (>200 %) | Approved | 27476412 |
| DrugRepV_1543 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | MEX_I_7 | NA | Flow cytometry | Decrease (50 %) | Approved | 27476412 |
| DrugRepV_1544 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Zika virus | MEX_I_7 | NA | Flow cytometry | No significant effect (50 %) | Approved, Investigational, Vet approved | 27476412 |
| DrugRepV_1545 | Daptomycin | Antiinfectives For Systemic Use | Bacterial infections | Zika virus | MEX_I_7 | NA | Flow cytometry | Increase (120 %) | Approved | 27476412 |
| DrugRepV_1546 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Zika virus | MEX_I_7 | NA | Flow cytometry | Increase (200 %) | Approved, Investigational | 27476412 |
| DrugRepV_1547 | Cyclosporine | Antineoplastic and Immunomodulating Agents; Sensory Organ | Immune disorders | Zika virus | DAK_41525 | NA | Flow cytometry | Increase (140 %) | Approved | 27476412 |
| DrugRepV_1548 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Zika virus | DAK_41525 | NA | Flow cytometry | Decrease (60 %) | Approved | 27476412 |
| DrugRepV_1549 | Ivermectin | Antiparasitic products, Insectisides and Repellents | Intestinal strongyloidiasis | Onchocerciasis | Zika virus | DAK_41525 | NA | Flow cytometry | Decrease (60 %) | Approved, Investigational, Vet approved | 27476412 |
| DrugRepV_1550 | Daptomycin | Antiinfectives For Systemic Use | Bacterial infections | Zika virus | DAK_41525 | NA | Flow cytometry | No significant effect | Approved | 27476412 |
| DrugRepV_1551 | Mefloquine | Antiparasitic products, Insectisides and Repellents | Malaria | Zika virus | DAK_41525 | NA | Flow cytometry | Increase (120 %) | Approved, Investigational | 27476412 |
| DrugRepV_1552 | Sertraline | Nervous System | Depressive disorder | Post-traumatic stress disorder | Obsessive-compulsive disorder | Panic disorder | Premenstrual dysphoric disorder | Social anxiety disorder | Zika virus | DAK_41525 | NA | Flow cytometry | Increase (120 %) | Approved | 27476412 |
| DrugRepV_1553 | Bortezomib | Antineoplastic and Immunomodulating Agents | Multiple Myeloma | Zika virus | DAK_41525 | NA | Flow cytometry | Decrease (>80 %) | Approved | 27476412 |
| DrugRepV_2125 | Sofosbuvir | Antiinfectives For Systemic Use | Hepatitis C virus | Acquired immunodeficiency syndrome | Zika virus | Paraiba | NA | Flow cytometry | Decrease (50 %) | Approved | 27902933 |
| DrugRepV_2126 | Sofosbuvir | Antiinfectives For Systemic Use | Hepatitis C virus | Acquired immunodeficiency syndrome | Zika virus | Paraiba | NA | Flow cytometry | Decrease (50 %) | Approved | 27902933 |
| DrugRepV_3200 | Andrographolide | NA | Ulcerative colitis and Upper respiratory tract infection | Chikungunya virus | E1:226VT | NA | Flow cytometry | Decrease (90 %) | Investigational | 26384169 |
| DrugRepV_3273 | 5-Tetradecyloxy-2-furoic Acid | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3274 | Orlistat | Alimentary Tract and Metabolism | Obesity | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27177310 |
| DrugRepV_3275 | Cerulenin | NA | Fungal infection | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3276 | Bafilomycin | Antibiotics | Bacterial infection | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Experimental | 27177310 |
| DrugRepV_3277 | AnnH18 | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3278 | AnnH14 | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3279 | KH-CB19 | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3280 | Anacardic Acid | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3281 | TAE684 | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3282 | Pimozide | Nervous System | Tourette Disorder | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3283 | Perphenazine | Nervous System | Psychosis | Nausea and vomiting in adults | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3284 | 6-Hydroxyflavone | NA | Anxiety-like disorders | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3285 | Prenylamine | Cardiovascular agents | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Withdrawn | 27177310 |
| DrugRepV_3286 | Felodipine | Cardiovascular agents | Hypertension | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27177310 |
| DrugRepV_3287 | Alsterpaullone | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Experimental | 27177310 |
| DrugRepV_3288 | Pazopanib | Antineoplastic and Immunomodulating Agents | Advanced renal cell cancer | Advanced soft tissue sarcoma | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3289 | Axitinib | Antineoplastic and Immunomodulating Agents | Cancer | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 27177310 |
| DrugRepV_3290 | Tivozanib | NA | Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Investigational | 27177310 |
| DrugRepV_3291 | Sorafenib | Antineoplastic and Immunomodulating Agents | Hepatocellular carcinoma | Renal cell carcinoma | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 27177310 |
| DrugRepV_3292 | Linifanib | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (50 %) | NA | 27177310 |
| DrugRepV_3293 | 5-Tetradecyloxy-2-furoic Acid | NA | NA | Influenza virus | NA |  | Flow cytometry | Decrease (100 %) | NA | 27177310 |
| DrugRepV_3294 | Cerulenin | NA | Fungal infection | Influenza virus | NA | | Flow cytometry | Decrease (100 %) | Approved | 27177310 |
| DrugRepV_3295 | Bafilomycin | Antibiotics | Bacterial infection | Influenza virus | NA | | Flow cytometry | Decrease (100 %) | Experimental | 27177310 |
| DrugRepV_3296 | Pimozide | Nervous System | Tourette Disorder | Influenza virus | NA | | Flow cytometry | Decrease (100 %) | Approved | 27177310 |
| DrugRepV_3297 | TIvozanib | NA | Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease | Influenza virus | NA | | Flow cytometry | Decrease (100 %) | Investigational | 27177310 |
| DrugRepV_3298 | Anacardic Acid | NA | NA | Chikungunya virus | NA | NA | Flow cytometry | Decrease (75 %) | NA | 27177310 |
| DrugRepV_3299 | Bafilomycin | Antibiotics | Bacterial infection | Chikungunya virus | NA | NA | Flow cytometry | Decrease (100 %) | Experimental | 27177310 |
| DrugRepV_3300 | Cerulenin | NA | Fungal infection | Chikungunya virus | NA | NA | Flow cytometry | Decrease (75 %) | Approved | 27177310 |
| DrugRepV_3301 | Pimozide | Nervous System | Tourette Disorder | Chikungunya virus | NA | NA | Flow cytometry | Decrease (90 %) | Approved | 27177310 |
| DrugRepV_3302 | TIvozanib | NA | Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease | Chikungunya virus | NA | NA | Flow cytometry | Decrease (90 %) | Investigational | 27177310 |
| DrugRepV_5485 | Pranlukast | Respiratory System | Allergic reaction | Zika virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved | 31786251 |
| DrugRepV_5486 | Conivaptan | Cardiovascular agents | Hypervolemic hyponatremia | Zika virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational | 31786251 |
| DrugRepV_5487 | Novobiocin | NA | Staphylococci infections | Zika virus | NA | NA | Flow cytometry | Decrease (50 %) | Approved, Investigational, Vet approved | 31786251 |
| DrugRepV_5700 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (50 %) | Approved | 12504563 |
| DrugRepV_5701 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (51 %) | Approved | 12504563 |
| DrugRepV_5702 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (52 %) | Approved | 12504563 |
| DrugRepV_5703 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | 16681 | | Flow cytometry | Decrease (50 %) | Approved | 12504563 |
| DrugRepV_5706 | Mycophenolic Acid | Antineoplastic and Immunomodulating Agents | Organ rejection (immunosuppressants) | Dengue virus | N1047 | | Flow cytometry | Decrease (97 %) | Approved | 12504563 |
| DrugRepV_5983 | Castanospermine | Antiviral | Dengue and Parainfluenza | Dengue virus | NA | | Flow cytometry | Decrease | Experimental | 15994763 |
| DrugRepV_5984 | Castanospermine | Antiviral | Dengue and Parainfluenza | Dengue virus | NA | | Flow cytometry | Decrease | Experimental | 15994763 |
| DrugRepV_5985 | Castanospermine | Antiviral | Dengue and Parainfluenza | Dengue virus | NA | | Flow cytometry | Decrease | Experimental | 15994763 |
| DrugRepV_5986 | Castanospermine | Antiviral | Dengue and Parainfluenza | Dengue virus | NA | | Flow cytometry | Decrease | Experimental | 15994763 |
| DrugRepV_6117 | FGI-106 | NA | NA | Dengue virus | NA | | Flow cytometry | Decrease (50 %) | NA | 19523489 |
| DrugRepV_6118 | FGI-106 | NA | NA | Dengue virus | NA | | Flow cytometry | Decrease (50 %) | NA | 19523489 |
| DrugRepV_6119 | FGI-106 | NA | NA | Dengue virus | NA | | Flow cytometry | Decrease (50 %) | NA | 19523489 |
| DrugRepV_6120 | FGI-106 | NA | NA | Dengue virus | NA | | Flow cytometry | Decrease (50 %) | NA | 19523489 |
| DrugRepV_6260 | HHA | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6261 | GNA | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6262 | UDA | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6263 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6264 | Mannan | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6270 | HHA | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6271 | GNA | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6272 | UDA | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6273 | Dextran Sulphate | Blood and Blood Forming Organs | Antithrombotic | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | Phase I | 19264337 |
| DrugRepV_6274 | Mannan | NA | NA | Dengue virus | New Guinea C (NGC) | | Flow cytometry | Decrease (50 %) | NA | 19264337 |
| DrugRepV_6312 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Dengue virus | NGC | | Flow cytometry | Decrease (86 %) | Approved, Investigational | 16309754 |
| DrugRepV_6313 | PI-88 | NA | Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma | Dengue virus | NGC | | Flow cytometry | Decrease (53 %) | Investigational | 16309754 |
| DrugRepV_6314 | Suramin | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | Dengue virus | NGC | | Flow cytometry | Decrease (92 %) | Investigational | 16309754 |
| DrugRepV_6315 | PPS | NA | NA | Dengue virus | NGC | | Flow cytometry | Decrease (76 %) | NA | 16309754 |
| DrugRepV_7226 | 2-(3-chlorophenoxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Flow cytometry | Decrease (17 %) | NA | 28068627 |
| DrugRepV_7227 | 2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Flow cytometry | Decrease (22 %) | NA | 28068627 |
| DrugRepV_7228 | 2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone | NA | NA | Yellow fever virus | NA | | Flow cytometry | Decrease (14 %) | NA | 28068627 |
| DrugRepV_7229 | 2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione | NA | NA | Yellow fever virus | NA | | Flow cytometry | Decrease (10 %) | NA | 28068627 |
| DrugRepV_7230 | 2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione | NA | NA | Yellow fever virus | NA | | Flow cytometry | Decrease (3 %) | NA | 28068627 |
| DrugRepV_7231 | 2-(3-chlorophenoxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Flow cytometry | Increase | NA | 28068627 |
| DrugRepV_7232 | 2-(3,4-dichlorophen oxy) acetaldehydethiosemicarbazone | NA | NA | Yellow fever virus | NA | | Flow cytometry | Increase | NA | 28068627 |
| DrugRepV_7233 | 2-(2,3-dichlorophenoxy) acetaldehyde thiosemicarbazone | NA | NA | Yellow fever virus | NA | | Flow cytometry | Increase | NA | 28068627 |
| DrugRepV_7234 | 2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione | NA | NA | Yellow fever virus | NA | | Flow cytometry | Increase | NA | 28068627 |
| DrugRepV_7235 | 2-(4-(4-chlorophenyl) thiazol-2-yl)hydrazono)ethyl)isoindoline-1,3-dione | NA | NA | Yellow fever virus | NA | | Flow cytometry | Increase | NA | 28068627 |
| DrugRepV_7262 | Heparin | Blood and Blood Forming Organs | Venous thrombosis | Japanese encephalitis virus | Nakayama | | Flow cytometry | Decrease (70 %) | Approved, Investigational | 16309754 |
| DrugRepV_7263 | PI-88 | NA | Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma | Japanese encephalitis virus | Nakayama | | Flow cytometry | Decrease (66 %) | Investigational | 16309754 |
| DrugRepV_7264 | Suramin | Antiparasitic products, Insectisides and Repellents | Sleeping sickness | Onchocerciasis | Japanese encephalitis virus | Nakayama | | Flow cytometry | Decrease (85 %) | Investigational | 16309754 |
| DrugRepV_7265 | PPS | NA | NA | Japanese encephalitis virus | Nakayama | | Flow cytometry | Decrease (70 %) | NA | 16309754 |
| DrugRepV_7266 | PI-88 | NA | Hepatocellular carcinoma | Liver cancer | Melanoma | Multiple myeloma | West Nile virus | NY-99 | | Flow cytometry | Decrease (66 %) | Investigational | 16309754 |
| DrugRepV_7319 | MJ-47 | NA | NA | Japanese encephalitis virus | JEVSRIP | | Flow cytometry | Decrease (50 %) | NA | 28394283 |
| DrugRepV_7320 | N-(6-methanesulfonyl-1,3-benzothiazol-2-yl)-4-[(4-nitro-1H-pyrazol-1-yl)methyl]benzamide | NA | NA | Japanese encephalitis virus | NS3 helicase | | Flow cytometry | Decrease (79 %) | NA | 27679979 |
| DrugRepV_7321 | N-[6-({[(thiophen-2-yl)formamido]methanethioyl}amino)-1,3-benzothiazol-2-yl]butanamide | NA | NA | Japanese encephalitis virus | NS3 helicase | | Flow cytometry | Decrease (73 %) | NA | 27679979 |